Answers are grounded in this paper and cite their sources.
Key Points The intensified standard-of-care regimens for younger patients with MCL do not overcome the deleterious effects of TP53 mutations. MCLs with TP53 mutations should be considered for alternative frontline treatment.
No takes yet. Share an insight, caveat, or question.
Eskelund et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: